DelveInsight’s “Irritable Bowel Syndrome Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Irritable Bowel Syndrome pipeline landscapes.
The report comprises Irritable Bowel Syndrome pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Irritable Bowel Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Irritable Bowel Syndrome pipeline products.
Irritable Bowel Syndrome Overview
Irritable bowel syndrome is one of the most commonly diagnosed gastrointestinal diseases. Irritable Bowel Syndrome, in the absence of any other causative disease, is defined as the presence of abdominal pain or discomfort with altered bowel habits. The etiology of Irritable bowel syndrome is broad and not clearly understood. However, the pathophysiology of Irritable Bowel Syndrome is broad and includes abnormalities involving motility, visceral sensation, brain-gut interaction, and psychosocial distress. Irritable Bowel Syndrome typically consists of abdominal pain or discomfort, altered bowel habits along with either constipation, diarrhea, or both. Other complaints in patients with Irritable Bowel Syndrome include bloating, distention, symptoms brought on my food intake, and a change in pain location, and stool pattern with time.
Some of the key takeaways from the Irritable Bowel Syndrome Pipeline Report:
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Octapharma USA, Amgen, Dova Pharmaceuticals, Novartis, etc., are developing therapies for the treatment of the Irritable Bowel Syndrome Market.
-
Emerging therapies such as Octagam, Nplate (AMG-531), Doptelet (Avatrombopag), Promacta (eltrombopag), are expected to have a significant impact on the Irritable Bowel Syndrome Market market in the coming years.
Get an overview of pipeline landscape @ Irritable Bowel Syndrome Clinical Trials Analysis
Irritable Bowel Syndrome Pipeline Therapies along with Key Players:
-
ORP-101: OrphoMed, Inc.
-
Blautix: 4D pharma, and others
Scope of Irritable Bowel Syndrome Pipeline Drug Insight
-
Coverage: Global
-
Major Players: OrphoMed, Inc., 4D pharma, and others.
-
Pipeline Therapies: ORP-101, Blautix, and others.
Table of Contents
|
1 |
Irritable Bowel Syndrome Report Introduction |
|
2 |
Irritable Bowel Syndrome Executive Summary |
|
3 |
Irritable Bowel Syndrome Overview |
|
4 |
Irritable Bowel Syndrome- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Irritable Bowel Syndrome Pipeline Therapeutics |
|
6 |
Irritable Bowel Syndrome Late Stage Products (Phase II/III) |
|
7 |
Irritable Bowel Syndrome Mid Stage Products (Phase II) |
|
8 |
Irritable Bowel Syndrome Early Stage Products (Phase I) |
|
9 |
Irritable Bowel Syndrome Preclinical Stage Products |
|
10 |
Irritable Bowel Syndrome Therapeutics Assessment |
|
11 |
Irritable Bowel Syndrome Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Irritable Bowel Syndrome Key Companies |
|
14 |
Irritable Bowel Syndrome Key Products |
|
15 |
Irritable Bowel Syndrome Unmet Needs |
|
16 |
Irritable Bowel Syndrome Market Drivers and Barriers |
|
17 |
Irritable Bowel Syndrome Future Perspectives and Conclusion |
|
18 |
Irritable Bowel Syndrome Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Related Reports:
Irritable Bowel Syndrome Market Market
DelveInsight’s ‘Irritable Bowel Syndrome Market-Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Irritable Bowel Syndrome Market Epidemiology
DelveInsight’s ‘Irritable Bowel Syndrome Market Epidemiology Forecast to 2030′ report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/